CN100379863C - 以串连表达方式制备天然人胸腺素α1的方法 - Google Patents
以串连表达方式制备天然人胸腺素α1的方法 Download PDFInfo
- Publication number
- CN100379863C CN100379863C CNB2005100500696A CN200510050069A CN100379863C CN 100379863 C CN100379863 C CN 100379863C CN B2005100500696 A CNB2005100500696 A CN B2005100500696A CN 200510050069 A CN200510050069 A CN 200510050069A CN 100379863 C CN100379863 C CN 100379863C
- Authority
- CN
- China
- Prior art keywords
- xho
- double digestion
- thymosin
- bgl
- bamh
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 238000000034 method Methods 0.000 title claims abstract description 20
- LCJVIYPJPCBWKS-NXPQJCNCSA-N thymosin Chemical compound SC[C@@H](N)C(=O)N[C@H](CO)C(=O)N[C@H](CC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@H](C(C)C)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](C(C)C)C(=O)N[C@H](CO)C(=O)N[C@H](CO)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@H]([C@H](C)O)C(=O)N[C@H](C(C)C)C(=O)N[C@H](CCCCN)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H](CCCCN)C(=O)N[C@H](CCCCN)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H](C(C)C)C(=O)N[C@H](C(C)C)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@H](CCC(O)=O)C(O)=O LCJVIYPJPCBWKS-NXPQJCNCSA-N 0.000 title claims description 21
- 108010046075 Thymosin Proteins 0.000 title claims description 15
- 102000007501 Thymosin Human genes 0.000 title claims description 15
- 239000012634 fragment Substances 0.000 claims abstract description 20
- 239000013612 plasmid Substances 0.000 claims abstract description 14
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 13
- 108020004705 Codon Proteins 0.000 claims abstract description 5
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 5
- 238000000746 purification Methods 0.000 claims abstract description 4
- 230000029087 digestion Effects 0.000 claims description 20
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims description 14
- 108020004707 nucleic acids Proteins 0.000 claims description 14
- 150000007523 nucleic acids Chemical class 0.000 claims description 14
- 102000039446 nucleic acids Human genes 0.000 claims description 14
- 108091008146 restriction endonucleases Proteins 0.000 claims description 14
- 125000003729 nucleotide group Chemical group 0.000 claims description 13
- 210000003000 inclusion body Anatomy 0.000 claims description 9
- 102000003960 Ligases Human genes 0.000 claims description 8
- 108090000364 Ligases Proteins 0.000 claims description 8
- 238000012258 culturing Methods 0.000 claims description 8
- 239000004471 Glycine Substances 0.000 claims description 7
- AVXURJPOCDRRFD-UHFFFAOYSA-N Hydroxylamine Chemical compound ON AVXURJPOCDRRFD-UHFFFAOYSA-N 0.000 claims description 7
- 239000002773 nucleotide Substances 0.000 claims description 7
- 102000004190 Enzymes Human genes 0.000 claims description 6
- 108090000790 Enzymes Proteins 0.000 claims description 6
- 241000588724 Escherichia coli Species 0.000 claims description 6
- 150000001413 amino acids Chemical class 0.000 claims description 5
- 238000003556 assay Methods 0.000 claims description 5
- 230000002650 habitual effect Effects 0.000 claims description 4
- 238000000926 separation method Methods 0.000 claims description 4
- JLXVRFDTDUGQEE-YFKPBYRVSA-N Gly-Arg Chemical compound NCC(=O)N[C@H](C(O)=O)CCCN=C(N)N JLXVRFDTDUGQEE-YFKPBYRVSA-N 0.000 claims description 3
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 claims description 3
- ZSZFTYVFQLUWBF-QXEWZRGKSA-N Val-Asp-Met Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CCSC)C(=O)O)N ZSZFTYVFQLUWBF-QXEWZRGKSA-N 0.000 claims description 3
- 238000000137 annealing Methods 0.000 claims description 3
- 238000003776 cleavage reaction Methods 0.000 claims description 3
- BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl beta-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 claims description 3
- 229930182817 methionine Natural products 0.000 claims description 3
- 108010005942 methionylglycine Proteins 0.000 claims description 3
- 230000007017 scission Effects 0.000 claims description 3
- IALQAMYQJBZNSK-WHFBIAKZSA-N Gly-Ser-Asn Chemical compound [H]NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(O)=O IALQAMYQJBZNSK-WHFBIAKZSA-N 0.000 claims 1
- 229920001184 polypeptide Polymers 0.000 abstract description 12
- 102000004196 processed proteins & peptides Human genes 0.000 abstract description 12
- 108090000765 processed proteins & peptides Proteins 0.000 abstract description 12
- 241000894006 Bacteria Species 0.000 abstract description 9
- 230000003321 amplification Effects 0.000 abstract description 6
- 238000003199 nucleic acid amplification method Methods 0.000 abstract description 6
- 238000002360 preparation method Methods 0.000 abstract description 3
- 238000003786 synthesis reaction Methods 0.000 abstract description 3
- 239000000203 mixture Substances 0.000 abstract description 2
- 108091033319 polynucleotide Proteins 0.000 abstract description 2
- 102000040430 polynucleotide Human genes 0.000 abstract description 2
- 239000002157 polynucleotide Substances 0.000 abstract description 2
- 230000008569 process Effects 0.000 abstract description 2
- 230000015572 biosynthetic process Effects 0.000 abstract 2
- 238000010276 construction Methods 0.000 abstract 2
- 101500028961 Homo sapiens Thymosin alpha-1 Proteins 0.000 abstract 1
- 238000000354 decomposition reaction Methods 0.000 abstract 1
- 238000001976 enzyme digestion Methods 0.000 abstract 1
- 238000001308 synthesis method Methods 0.000 abstract 1
- 101150084750 1 gene Proteins 0.000 description 7
- 238000001962 electrophoresis Methods 0.000 description 7
- 201000011510 cancer Diseases 0.000 description 6
- 206010028980 Neoplasm Diseases 0.000 description 5
- 238000006243 chemical reaction Methods 0.000 description 5
- 102000000588 Interleukin-2 Human genes 0.000 description 4
- 108010002350 Interleukin-2 Proteins 0.000 description 4
- 241000700605 Viruses Species 0.000 description 4
- 239000000872 buffer Substances 0.000 description 4
- 210000001744 T-lymphocyte Anatomy 0.000 description 3
- 238000005119 centrifugation Methods 0.000 description 3
- 238000005336 cracking Methods 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 238000000605 extraction Methods 0.000 description 3
- 230000036039 immunity Effects 0.000 description 3
- 238000009413 insulation Methods 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 238000012546 transfer Methods 0.000 description 3
- FRXSZNDVFUDTIR-UHFFFAOYSA-N 6-methoxy-1,2,3,4-tetrahydroquinoline Chemical compound N1CCCC2=CC(OC)=CC=C21 FRXSZNDVFUDTIR-UHFFFAOYSA-N 0.000 description 2
- KLKHFFMNGWULBN-VKHMYHEASA-N Asn-Gly Chemical compound NC(=O)C[C@H](N)C(=O)NCC(O)=O KLKHFFMNGWULBN-VKHMYHEASA-N 0.000 description 2
- 206010019799 Hepatitis viral Diseases 0.000 description 2
- 235000001014 amino acid Nutrition 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 238000002512 chemotherapy Methods 0.000 description 2
- 230000007812 deficiency Effects 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 229960001438 immunostimulant agent Drugs 0.000 description 2
- 239000003022 immunostimulating agent Substances 0.000 description 2
- 230000003308 immunostimulating effect Effects 0.000 description 2
- 230000000527 lymphocytic effect Effects 0.000 description 2
- 238000001556 precipitation Methods 0.000 description 2
- 238000001959 radiotherapy Methods 0.000 description 2
- 102220023256 rs387907547 Human genes 0.000 description 2
- 210000001541 thymus gland Anatomy 0.000 description 2
- 201000001862 viral hepatitis Diseases 0.000 description 2
- 108010077805 Bacterial Proteins Proteins 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 1
- BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 description 1
- 241001198387 Escherichia coli BL21(DE3) Species 0.000 description 1
- 206010062016 Immunosuppression Diseases 0.000 description 1
- 102000008070 Interferon-gamma Human genes 0.000 description 1
- 108010074328 Interferon-gamma Proteins 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 102000008072 Lymphokines Human genes 0.000 description 1
- 108010074338 Lymphokines Proteins 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 108010078233 Thymalfasin Proteins 0.000 description 1
- 102400000800 Thymosin alpha-1 Human genes 0.000 description 1
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 239000008004 cell lysis buffer Substances 0.000 description 1
- 230000011748 cell maturation Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 201000010989 colorectal carcinoma Diseases 0.000 description 1
- 208000035250 cutaneous malignant susceptibility to 1 melanoma Diseases 0.000 description 1
- 238000013016 damping Methods 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000004043 dyeing Methods 0.000 description 1
- 238000003912 environmental pollution Methods 0.000 description 1
- 239000013613 expression plasmid Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 229940044627 gamma-interferon Drugs 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000001506 immunosuppresive effect Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- -1 isopropyl- Chemical group 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 239000006193 liquid solution Substances 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- 230000000116 mitigating effect Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 238000002264 polyacrylamide gel electrophoresis Methods 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- 238000005063 solubilization Methods 0.000 description 1
- 230000007928 solubilization Effects 0.000 description 1
- 206010041823 squamous cell carcinoma Diseases 0.000 description 1
- 208000017572 squamous cell neoplasm Diseases 0.000 description 1
- 238000010408 sweeping Methods 0.000 description 1
- 230000009182 swimming Effects 0.000 description 1
- 238000010189 synthetic method Methods 0.000 description 1
- NZVYCXVTEHPMHE-ZSUJOUNUSA-N thymalfasin Chemical compound CC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O NZVYCXVTEHPMHE-ZSUJOUNUSA-N 0.000 description 1
- 229960004231 thymalfasin Drugs 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
Landscapes
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Description
Claims (1)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNB2005100500696A CN100379863C (zh) | 2005-06-14 | 2005-06-14 | 以串连表达方式制备天然人胸腺素α1的方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNB2005100500696A CN100379863C (zh) | 2005-06-14 | 2005-06-14 | 以串连表达方式制备天然人胸腺素α1的方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1724663A CN1724663A (zh) | 2006-01-25 |
CN100379863C true CN100379863C (zh) | 2008-04-09 |
Family
ID=35924293
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CNB2005100500696A Active CN100379863C (zh) | 2005-06-14 | 2005-06-14 | 以串连表达方式制备天然人胸腺素α1的方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN100379863C (zh) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101544693B (zh) * | 2008-12-11 | 2012-06-06 | 中国人民解放军第四军医大学 | 重组胸腺素α1二串体蛋白及其制备方法 |
CN102676534B (zh) * | 2012-04-12 | 2014-07-16 | 上海育臣生物工程技术有限公司 | 一种利用内含肽制备胸腺素多肽的方法 |
CN103789321B (zh) * | 2014-02-24 | 2016-06-08 | 东北制药集团股份有限公司 | 一种重组人胸腺肽α1的制备方法 |
CN110964117A (zh) * | 2019-10-21 | 2020-04-07 | 哈尔滨医科大学 | 聚乙二醇修饰的人胸腺素β4二串体蛋白及其制备方法和应用 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1150602A (zh) * | 1996-05-31 | 1997-05-28 | 中国人民解放军军事医学科学院卫生学环境研究所 | 人胸腺素α原及其制备方法 |
CN1258747A (zh) * | 1998-12-30 | 2000-07-05 | 中国人民解放军第四军医大学 | 以大肠杆菌制备4串体胸腺素α1 |
CN1532289A (zh) * | 2003-03-20 | 2004-09-29 | 中国人民解放军军事医学科学院生物工 | 用重组大肠杆菌制备N-末端乙酰化修饰的胸腺素α的方法 |
-
2005
- 2005-06-14 CN CNB2005100500696A patent/CN100379863C/zh active Active
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1150602A (zh) * | 1996-05-31 | 1997-05-28 | 中国人民解放军军事医学科学院卫生学环境研究所 | 人胸腺素α原及其制备方法 |
CN1258747A (zh) * | 1998-12-30 | 2000-07-05 | 中国人民解放军第四军医大学 | 以大肠杆菌制备4串体胸腺素α1 |
CN1532289A (zh) * | 2003-03-20 | 2004-09-29 | 中国人民解放军军事医学科学院生物工 | 用重组大肠杆菌制备N-末端乙酰化修饰的胸腺素α的方法 |
Non-Patent Citations (3)
Title |
---|
胸腺素alpha-1基因的克隆、表达及其对淋巴细胞增殖的影响. 宫照龙.安徽医科大学硕士学位论文. 2004 * |
胸腺素α1串连体基因的克隆表达、产物纯化及其生物学活性研究. 薛晓畅.第四军医大学硕士学位论文. 2001 * |
胸腺素α1基因的克隆表达及其生物活性. 石继红等.中国生物化学与分子生物学报,第17卷第3期. 2001 * |
Also Published As
Publication number | Publication date |
---|---|
CN1724663A (zh) | 2006-01-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DK172013B1 (da) | DNA, vektor indeholdende dette DNA, vært transformeret med vektoren,polypeptid indeholdt i DNA'et og salt deraf, aggregat indeholdende polypeptidet samt pharmaceutisk sammensætning indeholdende polypeptidet eller aggregatet. | |
JPS63251095A (ja) | 新規融合蛋白質およびその精製方法 | |
NO165201B (no) | Fremgangsmaate for fremstilling av hybrid munamleukocyttinterferoner paa 165-166 aminosyrer omfattende en subsekvens fra human leukocytt-interferon a og en subsekvens fra human leukocytt-interferon b eller d. | |
CN106674354B (zh) | 一种鸡干扰素IFN-λ与IFN-α的融合蛋白 | |
CN100379863C (zh) | 以串连表达方式制备天然人胸腺素α1的方法 | |
CN1044479C (zh) | 抗凝血酶多肽的制备方法 | |
CN106939042A (zh) | 一种猪α干扰素及其应用 | |
CN102286490A (zh) | 一种鸡干扰素γ的制备复性方法 | |
CN101376887B (zh) | 猪口蹄疫重组免疫复合肽的制备方法及应用 | |
CN108794638A (zh) | 一种重组牛长效干扰素α及制备此长效干扰素的融合蛋白及其制备方法 | |
CN100436576C (zh) | 一株产生纳豆激酶的枯草芽孢杆菌 | |
CN109627298B (zh) | 一种具有抗hiv-1作用的重组鞭毛蛋白及其编码基因和应用 | |
CN107286255A (zh) | 一种由鸡白蛋白、鸡干扰素γ和鸡干扰素α组成的融合蛋白及其制备方法 | |
CN101560248A (zh) | 减毒肠毒素c2超抗原突变蛋白及其制备方法和应用 | |
CN102827289A (zh) | 猪圆环病毒2型Cap蛋白和胸腺素α1融合蛋白及应用 | |
CN102676534B (zh) | 一种利用内含肽制备胸腺素多肽的方法 | |
CN103012578B (zh) | 一种重组猪白细胞介素2及其编码基因和表达方法 | |
CN113121672B (zh) | 猫干扰素γ的可溶性原核表达和纯化方法及应用 | |
CN108840934B (zh) | 一种重组羊长效干扰素τ及制备此长效干扰素的融合蛋白及其制备方法 | |
CN1861635A (zh) | 人胰高血糖素相关肽-2类似物 | |
CN103937828A (zh) | 一种猪干扰素α1与胸腺肽α1融合蛋白的制备技术 | |
CN100425697C (zh) | 一种人白细胞介素21的核苷酸序列及生产成熟的人白细胞介素21的方法和应用 | |
CN109851666A (zh) | 一种重组猪α-干扰素蛋白及其编码基因与应用 | |
CN108794644A (zh) | 一种由牛白细胞介素2、牛干扰素γ和牛干扰素α组成的融合蛋白及其制备方法 | |
CN1258747A (zh) | 以大肠杆菌制备4串体胸腺素α1 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
ASS | Succession or assignment of patent right |
Owner name: SHANGHAI ENTS BIOTECHNOLOGY CO., LTD. Free format text: FORMER OWNER: ZHEJIANG UNIVERSITY Effective date: 20140731 |
|
C41 | Transfer of patent application or patent right or utility model | ||
COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 310027 HANGZHOU, ZHEJIANG PROVINCE TO: 200120 PUDONG NEW AREA, SHANGHAI |
|
TR01 | Transfer of patent right |
Effective date of registration: 20140731 Address after: 200120, room 2, building 3377, 321, Kang Xin Road, Shanghai, Pudong New Area Patentee after: Shanghai ENTS Biotechnology Co., Ltd. Address before: 310027 Hangzhou, Zhejiang Province, Xihu District, Zhejiang Road, No. 38, No. Patentee before: Zhejiang University |
|
ASS | Succession or assignment of patent right |
Owner name: HUNAN FANGSHENG YUCHEN BIOLOGICAL TECHNOLOGY CO., Free format text: FORMER OWNER: SHANGHAI ENTS BIOTECHNOLOGY CO., LTD. Effective date: 20150820 |
|
C41 | Transfer of patent application or patent right or utility model | ||
TR01 | Transfer of patent right |
Effective date of registration: 20150820 Address after: 410295, building 4, building 402, building 789, Lu Song Road, hi tech Development Zone, Hunan, Changsha Patentee after: Hunan Sheng Yuchen Biotechnology Co. Ltd. Address before: 200120, room 2, building 3377, 321, Kang Xin Road, Shanghai, Pudong New Area Patentee before: Shanghai ENTS Biotechnology Co., Ltd. |
|
TR01 | Transfer of patent right |
Effective date of registration: 20201215 Address after: 570316 No. A-8, national high tech Industrial Development Zone, Haikou City, Hainan Province Patentee after: HAINAN DOCTOR PHARMACEUTICAL Co.,Ltd. Address before: Room 402, 4 / F, complex building, 789 lushong Road, high tech Development Zone, Changsha City, Hunan Province Patentee before: HUNAN FANGSHENG YUCHEN BIOTECHNOLOGY Co.,Ltd. |
|
TR01 | Transfer of patent right | ||
TR01 | Transfer of patent right | ||
TR01 | Transfer of patent right |
Effective date of registration: 20210611 Address after: No. 206, Kaiyuan Avenue, Science City, Guangzhou Economic and Technological Development Zone, Guangdong 510000 Patentee after: GUANGDONG JIDA GENETIC MEDICINE ENGINEERING RESEARCH CENTER Co.,Ltd. Address before: 570316 No. A-8, national high tech Industrial Development Zone, Haikou City, Hainan Province Patentee before: HAINAN DOCTOR PHARMACEUTICAL Co.,Ltd. |